One of the most persistent misconceptions about breast implants is that they come with an expiration date. I hear some version of this question from patients almost every week, something like “how long will my implants actually last”, “how will I know if something’s wrong?”, or “can this be my last surgery?”. Those are fair questions, and they deserve a more precise answer than the old rule of thumb that implants should be swapped out every 10 years. That guidance isn’t current FDA policy, and it doesn’t reflect what the long-term data actually shows.

Every silicone breast implant sold in the U.S. carries an FDA-mandated warning that implants are not designed to last a lifetime. That doesn’t mean rupture is likely soon after surgery, and it doesn’t mean every implant needs to come out on a schedule. In the large, FDA-mandated studies that supported approval of today’s major implant brands, confirmed or suspected rupture in primary augmentation patients was low in the first several years, generally under 3% within the first three years across major U.S. manufacturers.

Rupture risk isn’t flat over time, though. It’s cumulative, the longer an implant has been in place, the more opportunities it has had to develop a weakness in the shell from ordinary flexing, fold stress, or, less commonly, surgical or external trauma. Across every brand studied, rupture rates climb the further out from surgery you look, with the most consistent jump showing up somewhere in the 6-to-10-year range.

Why “The Rupture Rate” Isn’t One Number

Ask five different sources for “the” breast implant rupture rate and you’ll get five different answers. That’s not because someone is wrong. It’s because the studies behind those numbers aren’t measuring the same thing.

Rates vary based on:

  • How rupture was detected. Studies that actively screen every patient with MRI find more ruptures than studies that only follow up when a patient reports symptoms, because a meaningful share of ruptures are “silent”: no pain, no visible change, no way to know without imaging.
  • How long patients were followed. A study reporting a 3-year rate and a study reporting a 10-year rate on the same implant will look very different, and neither one is wrong.
  • What the surgery was for. Rupture rates in primary augmentation are consistently lower than in revision surgery or reconstruction, where tissue and healing conditions differ.
  • Implant generation and shell technology. Gel cohesiveness and shell engineering have both improved over the past two decades, so older implant generations don’t necessarily predict how newer ones perform.

This is why comparing a headline number from one brand’s 3-year data to another brand’s 10-year data can be misleading even when both studies were done well. Any honest comparison has to hold the follow-up period, and the screening method, constant.

implant rupture risk

What The Long-Term Data Actually Shows

The most reliable long-term numbers come from the FDA-mandated “core studies” each major manufacturer conducted to get its implants approved, tracking real patients with scheduled MRI screening over a decade. In primary augmentation patients:

Published Cumulative Rupture Rate*

Time Since Surgery

Within 3 years: Generally under 3% across major manufacturers
By about 6 years: Roughly 1% to 2%, depending on brand
By 10 years: Roughly 9% up to the low-to-mid 20s (percent), depending on brand, implant generation, and how rigorously patients were screened

*primary augmentation, major U.S. brands

That 10-year range is wide, and it’s a real one, not a data error. It reflects genuine differences between studies and, likely, real differences between implant designs, layered on top of the detection-method differences described above. It also means any specific percentage you see quoted for a “10-year rupture rate” should come with a follow-up question: which study, which implant, and how were patients screened?

Independent research outside the manufacturer studies tends to land in a broadly similar range once you’re a decade or more out, with some cohorts reporting rupture in roughly 1 in 10 implants by 13 years of age. Data much beyond that window is thin. Most published studies stop around 10 years, so specific claims about 15- or 20-year rupture rates should be treated with real caution, regardless of where you encounter them.

The single most useful thing you can do is follow the FDA’s imaging schedule: first screening at 5 to 6 years, then every 2 to 3 years after that, sooner if anything feels different.

The same implant can produce two very different numbers, and that’s the part patients rarely hear

Here’s a real example that I think does more to explain rupture-rate data than any single percentage could. One major manufacturer, Mentor, tracked its MemoryGel implant in its own FDA core study, with patients scheduled for MRI screening at set intervals over 10 years. That study found a cumulative rupture rate of 24.2% at 10 years.

A separate, independent study (Maxwell et al., Aesthetic Surgery Journal, 2021) followed 777 patients with that same implant at a single surgical practice, where screening happened less intensively and on a more real-world schedule, saw a 10-year rupture rate of 1.6%.

Same implant. Same 10-year time horizon. A more than 15-fold difference in the reported rate. Neither number is wrong, and this isn’t a case of one study being sloppy. The core study looked for rupture aggressively and on a fixed schedule, which is exactly the kind of screening that catches silent, symptom-free ruptures that would otherwise go unnoticed. The real-world study reflects how often patients were actually imaged in ordinary practice, which for most people is less often than a research protocol.

The takeaway I give my own patients is this. How often you’re actually screened changes how many ruptures get caught. That’s exactly why I focus on the FDA’s screening schedule below rather than asking patients to memorize a single headline percentage for their brand of implant. It’s also the most likely explanation for the steep jump you sometimes see in a manufacturer’s 10-year data compared to its 6-year data: more thorough imaging later in a study catches silent ruptures that earlier check-ins missed. That’s a change in detection, not necessarily a sudden change in the implant itself.

Current FDA Guidelines on Screening

In 2020, the FDA updated its recommendations for monitoring silicone gel implants, and this remains the standard I follow with my own patients:

  • First screening at 5 to 6 years after surgery, even without symptoms, using either MRI or ultrasound.
  • Repeat screening every 2 to 3 years after that, again regardless of symptoms.
  • An MRI at any time symptoms appear: new pain, swelling, hardening, a change in breast shape or size, or an uncertain ultrasound finding.
  • Saline implants don’t require this routine imaging, because rupture in a saline implant is usually obvious (the breast visibly deflates). Silicone rupture is frequently silent, which is the whole reason imaging surveillance matters.

The FDA also requires every patient to receive a patient device card after surgery, documenting the specific implant style, size, lot number, and a unique device identifier, along with a link to that implant’s boxed warning and patient decision checklist. If you don’t know which implant you have, this card, or your surgical records, is where to look.

Do You Need Replacement Just Because Time Has Passed?

No. The “replace every 10 years” guidance patients often repeat isn’t current FDA policy and isn’t well supported by the data. A large majority of implants are still intact and functioning well at 10 years, even in the studies with higher reported rupture rates.

What the evidence supports is monitoring, not automatic replacement:

  • If screening imaging shows your implant is intact, there’s generally no rupture-based reason to replace it.
  • If imaging confirms rupture, even a silent one with no symptoms, replacement or removal is generally recommended, since retained ruptured silicone can, over time, migrate beyond the capsule in a minority of cases.
  • Symptoms like new firmness, pain, shape change, or asymmetry warrant evaluation regardless of how long it’s been since surgery.
  • Reasons for replacement aren’t limited to rupture. Capsular contracture, a desire for a size or style change, and normal soft-tissue changes over time are common, separate reasons patients choose revision surgery.

One caveat, based on my own clinical experience rather than a published study: replacing implants before rupture and potential capsular contracture set in tends to make for a more straightforward, more predictable surgery with a quicker recovery. I want to be transparent that this is a personal observation, not something I’m aware of being validated in the research.

The Bottom Line

Modern silicone implants are well studied, and the honest picture is reassuring in the early years, with a real, well-documented increase in rupture risk the longer an implant has been in place. That’s not a fixed expiration date, but it’s not a lifetime guarantee either. The single most useful thing you can do is follow the FDA’s imaging schedule: first screening at 5 to 6 years, then every 2 to 3 years after that, sooner if anything feels different. That turns “when do I need to replace my implants” from a guess into something your surgeon can actually answer by looking at your implant, not the calendar.

A rupture-rate percentage on its own can’t tell you the condition of your implants; only imaging can. If you’re due for screening, unsure what implant you have, or have questions about your specific situation, that’s exactly the kind of conversation worth having at a consultation rather than trying to extrapolate from a percentage online.

FAQs

It depends heavily on the study. Published rates for primary augmentation with silicone implants are generally under 3% within the first 3 years, roughly 1% to 2% by 6 years, and range from about 9% up to the low-to-mid 20s (percent) by 10 years, depending on the brand, implant generation, and how actively patients were screened for rupture.

No. That guidance is not current FDA policy and isn’t well supported by the long-term data. Most implants are still intact at 10 years. The FDA recommends monitoring with MRI or ultrasound on a schedule rather than automatic replacement based on age alone.

Silicone implant rupture is frequently “silent,” meaning it causes no pain or visible change. Imaging (MRI or ultrasound) is the only reliable way to detect it, which is why the FDA recommends scheduled screening even without symptoms. Saline implant rupture is usually obvious because the breast visibly deflates.

The FDA recommends a first MRI or ultrasound at 5 to 6 years after surgery, then repeat imaging every 2 to 3 years after that, regardless of symptoms. An MRI is also recommended any time you notice pain, swelling, hardening, or a change in breast shape or size.

Because the studies aren’t measuring the same thing. Rates differ based on how rupture was detected (active MRI screening finds more silent ruptures than symptom-based follow-up), how long patients were followed, whether the surgery was primary augmentation versus revision or reconstruction, and the implant’s generation and shell technology.

Saline and silicone implants can both rupture, but the FDA’s routine imaging recommendation applies specifically to silicone implants, because silicone rupture is often silent. Saline rupture is usually immediately obvious without imaging, since the implant deflates and the change in breast volume is visible.

Sources: Manufacturer core clinical studies published in peer-reviewed journals (Plastic and Reconstructive Surgery, Aesthetic Surgery Journal) as available at the time of writing, including Maxwell et al., “Safety and Effectiveness of Silicone Gel-Filled Breast Implants in Primary Augmentation Patients,” Aesthetic Surgery Journal, 2021, for real-world Mentor data. Figures shown reflect primary augmentation cohorts and do not include revision or reconstruction patients, whose reported rates differ. This is not an exhaustive account of every study published on each device.

This article is for general educational purposes and isn’t a substitute for individualized medical advice. Rupture rates cited reflect published, peer-reviewed, and FDA-mandated study data available at the time of writing; individual risk depends on your specific implant, surgical history, and other factors best assessed in person.